Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial Conus, P., Berk, M., Cotton, S. M., Kader, L., Macneil, C., Hasty, M. K., Hallam, K., Lambert, M., Murphy, B. P. and McGorry, P. D. 2015, Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial, European psychiatry, vol. 30, no. 8, pp. 975-982, doi: 10.1016/j.eurpsy.2015.09.009. Attached Files Name Description MIMEType Size Downloads Title Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial Author(s) Conus, P. Berk, M. orcid.org/0000-0002-5554-6946 Cotton, S. M. Kader, L. Macneil, C. Hasty, M. K. Hallam, K. Lambert, M. Murphy, B. P. McGorry, P. D. Journal name European psychiatry Volume number 30 Issue number 8 Start page 975 End page 982 Total pages 8 Publisher Elsevier Place of publication Amsterdam, The Netherlands Publication date 2015-11 ISSN 1778-3585 Keyword(s) Antipsychotic treatment Bipolar disorder First episode Mania Psychosis Summary BACKGROUND: Treatment strategies for mental disorders may vary according to illness stage. However no data currently exist to guide treatment in first episode psychotic mania. The aim of this study was to compare the safety and efficacy profile of chlorpromazine and olanzapine, as add-on to lithium, in patients with a first episode of psychotic mania, expecting better safety profile and adherence to olanzapine but similar efficacy for both treatments. METHODS: Data from 83 patients were collected in an 8-week randomised controlled trial on clinical variables, side effects, vital signs, and weight. Analyses of treatment differences over time were based on intent-to-treat principles. Kaplan-Meier estimated survival curves were used to analyse time-to-event data and mixed effects models repeated measures analysis of variance were used to determine treatment group differences over time on safety and efficacy measures. RESULTS: Ethics committee approval to delay informed consent procedure until recovery from the acute episode allowed the inclusion of 83 patients highly representative of those treated in the public sector. Contrary to our hypotheses, safety profile of both medications was similar. A signal for higher rate (P=.032) and earlier occurrence (P=.043) of mania remission was observed in the olanzapine group which did not survive correction for multiple comparisons. CONCLUSIONS: Olanzapine and chlorpromazine have a similar safety profile in a uniquely representative cohort of patients with first episode psychotic mania. The possibility for a greater impact of olanzapine on manic symptoms leading to earlier remission of the episode needs exploration in a large sample. Language eng DOI 10.1016/j.eurpsy.2015.09.009 Field of Research 11 Medical And Health Sciences 17 Psychology And Cognitive Sciences 111502 Clinical Pharmacology and Therapeutics Socio Economic Objective 920410 Mental Health HERDC Research category C1.1 Refereed article in a scholarly journal Copyright notice ©2015, Elsevier Persistent URL http://hdl.handle.net/10536/DRO/DU:30079893 Document type: Journal Article Collections: Faculty of Health School of Medicine Related Links Link Description Connect to published version Go to link with your DU access privileges   Author URL Go to link with your DU access privileges     Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved. Versions Version Filter Type Fri, 27 Nov 2015, 11:42:03 EST Fri, 27 Nov 2015, 11:44:44 EST Sat, 28 Nov 2015, 04:02:13 EST Fri, 15 Jan 2016, 05:07:04 EST Thu, 25 Feb 2016, 14:32:29 EST Thu, 25 Feb 2016, 14:33:27 EST Wed, 09 Nov 2016, 11:34:13 EST Filtered Full Citation counts:   Cited 17 times in TR Web of Science Cited 18 times in Scopus Search Google Scholar Access Statistics: 515 Abstract Views, 2 File Downloads  -  Detailed Statistics Created: Fri, 27 Nov 2015, 11:44:44 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.